Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EGQMP
ADC Name
BAT8006
Synonyms
BAT 8006; BAT-8006; BAT8006
   Click to Show/Hide
Organization
Bio-Thera Solutions, Ltd.
Drug Status
Phase 1
Indication
In total 4 Indication(s)
Fallopian tube cancer
Phase 2
Clinical Trial
Ovarian cancer
Phase 2
Clinical Trial
Peritoneal cancer
Phase 2
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
7 to 8
Antibody Name
Undisclosed
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Exatecan
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05378737
Phase 1
A multicenter, open phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BAT8006 for injection in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05378737  Clinical Status Phase 1
Clinical Description A multicenter, open phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BAT8006 for injection in patients with advanced solid tumors.
References
Ref 1 A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of BAT8006 for Injection in Patients With Advanced Solid Tumors, NCT05378737